Also trades as: BUX.CN (CNQ) · $vol 0M
BMKDF OTC
BioMark Diagnostics Inc.
1W: +6.8%
1M: +7.2%
3M: -6.0%
YTD: +12.5%
1Y: +60.8%
3Y: +81.2%
5Y: +92.9%
$0.39
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$40.5M
52W Range0.212-0.5044
Volume100
Avg Volume3,922
Beta-0.31
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORashid Ahmed Maula Bux
Employees9
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2015-03-23
Websitebiomarkdiagnostics.com
3851 Shell Road
Richmond, BC V6X 2W2
CA
Richmond, BC V6X 2W2
CA
604 370 0779
About BioMark Diagnostics Inc.
BioMark Diagnostics Inc. is an oncology-focused firm that develops sophisticated diagnostic tools for cancer. These solutions are designed to aid in the identification of the disease, its ongoing monitoring, and the assessment of initial therapeutic interventions. The company has a research partnership with the Icahn School of Medicine, under which they conduct clinical studies concentrating on the early detection of lung cancer. Established in 2014, BioMark Diagnostics Inc. has its main office in Richmond, Canada, and functions as a subsidiary of Biomark Technologies Inc.
Latest News
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
BioMark: 2025 Achievements & 2026 Vision
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Recent Insider Trades
No insider trades found